rcca-header
Clinical Trials

A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

Type of Cancer
Lung
Phase
Division (Location)
Bethesda, MD
Study ID
NCT#
Brief Description
A Randomized, Phase 3, Open-Label Study of Combinations of REGN2810 (ANTI-PD-1 Antibody), Ipilimumab (ANTI-CTLA-4 Antibody), and Platinum-Based Doublet Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with Tumors Expressing PD-L1 <50%

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.